• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6

    Benzinga·05/19/2026 20:07:55
    Listen to the news

    Abstracts:

    LB0003

    Oral Presentation    		 AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with Rheumatologic Diseases
    Presenting Author: Norman B. Gaylis, M.D., F.A.C.P., M.A.C.R.

    Rheumatologist, Arthritis & Rheumatic Disease Specialties
    Session: Late Breaking Abstracts
    Date/Time/Location: Saturday, June 6, 2026 at 12:00 – 1:15 pm BST, Room: N3
    OP0129

    Oral Presentation    		 AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab was Highly Effective in Severe Sjögren Disease: Experience in First Patient Treated
    Presenting Author: Norman B. Gaylis, M.D., F.A.C.P., M.A.C.R.

    Rheumatologist, Arthritis & Rheumatic Disease Specialties
    Session: Clinical Abstract Sessions: Positive Clinical Trials - a new era in Sjögren's Disease
    Date/Time/Location: Wednesday, June 3, 2026 at 4:30 – 5:45 pm BST, Room: N3
    POS0355

    Poster Tour    		 AB-101, an Allogeneic NK Cell Therapy, in Combination with Anti-CD20 Monoclonal Antibodies, Consistently Achieves Deep B-cell Depletion Comparable with CAR T Cell Therapies in Patients with Rheumatologic Diseases
    Presenting Author: Heather Raymon, Ph.D.

    SVP, Research & Early Development, Artiva Biotherapeutics
    Session: Basic Poster Tours: Another one BITes the CAR-T
    Date/Time/Location: Saturday, June 6, 2026 at 10:15 – 11:15 am BST, Room: Poster Tour II
    POS1177

    Poster View    		 Robust and Durable Clinical Responses Observed Following Treatment with AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab in Patients with Severe Rheumatoid Arthritis and Inadequate Response to Multiple Prior Targeted Therapies
    Presenting Author: Guillermo J. Valenzuela, M.D., F.A.C.R.

    Medical Director, Integral Rheumatology & Immunology Specialists (IRIS)
    Session: Poster View VIII
    Date/Time/Location: Saturday, June 6, 2026 at 10:15 – 11:15 am BST, Room: Poster View
    AB0345

    Publication Only    		 Treatment with an Allogeneic NK Cell Therapy, AB-101, in Combination with Anti-CD20 Antibodies in Immune-mediated Diseases Demonstrates a Favorable Safety Profile and Comparable B-cell Depletion to CD19 CAR T Therapies
      Subhashis Banerjee, M.D.

    Chief Medical Officer, Artiva Biotherapeutics